Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: site specific immunomodulators - Qu Biologics

Drug Profile

Research programme: site specific immunomodulators - Qu Biologics

Alternative Names: SSI - Qu Biologics

Latest Information Update: 25 May 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qu Biologics
  • Class Bacterial antigens; Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Cancer

Most Recent Events

  • 20 May 2021 Preclinical trials in Autoimmune disorders in Canada (SC) (Qu Biologics pipeline, May 2021)
  • 19 May 2021 Preclinical trials in Cancer in Canada (SC) (Qu Biologics pipeline, May 2021)
  • 12 May 2021 Qu Biologics files for patent protection for Site Specific Immunomodulators (SSIs) for the treatment of perioperative immune dysfunction and prevention of cancer metastasis
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top